Composition:
Each film-coated tablet contains 50 mg Propentofilline.

Pharmacological Classification:
C8 Vascular medicines.

Pharmacological Action:
Propentofilline stimulates cerebral blood flow in dogs and simultaneously reduces cerebral vascular resistance. It also causes a dose-dependant increase in coronary arterial blood flow and has a slight to moderate inhibitory effect on platelet aggregation. An improvement in the relative flow rate of lactacidoxic and aged canine erythrocytes has been demonstrated in vitro. It is rapidly and completely absorbed after oral administration and is metabolised rapidly. It is excreted mainly via the kidneys.

Indications:
Indicated in geriatric dogs with circulatory disorders involving the microcirculation. May be useful in alleviating tiredness and apathy, stiff gait, difficulty in rising and walking, lack of appetite, wasting, alopecia, dull and rough coat in geriatric dogs.

Contra-indications:
Hypersensitivity to Propentofilline.

Warnings:

• For use in dogs only.
• Not to be used in food producing animals.

Dosage and Directions for Use:

• ADMINISTER ON AN EMPTY STOMACH.
• Provided not otherwise prescribed, the dose is one tablet per 10 kg body mass per day, to be administered as a divided dose, twice daily.
• For example:
• • Up to 5 kg body mass: 0,25 tablet twice a day
  • Up to 10 kg body mass: 0,5 tablet twice a day
  • Up to 20 kg body mass: 1,0 tablet twice a day
  • Up to 30 kg body mass: 1,5 tablets twice a day
  • Up to 40 kg body mass: 2,0 tablets twice a day
  • Up to 50 kg body mass: 2,5 tablets twice a day
  • Up to 60 kg body mass: 3,0 tablets twice a day
• The film-coated tablets can be used for direct oral administration or they can be hidden in a small ball of food or be crushed and mixed with the food and then offered for spontaneous consumption.
• The compound should be administered daily over an extended period.

Side Effects and Special Precautions:
The following side effects may occur: sedation, allergic skin reactions (e.g. itching, urticaria), increase or reduction in appetite, dyspnoea, tachycardia and vomiting. In addition, weakness of the hind legs, a change in the red blood cell count and increased thirst may occur.

Identification:
Ochre coloured, biconvex, film-coated tablets, 7 mm in diameter with a breakline on one side.

Storage Instructions:
Store below 25 ºC.

Keep out of reach of children and uninformed persons.

Presentation:
Blister packs containing 2 x 30 tablets each.

Registration holder:
Intervet S.A. (Pty) Ltd
Co. Reg. No. 1991/006580/07